Total Valuation
Consun Pharmaceutical Group Ltd. has a market cap or net worth of €1.23B. The enterprise value is €6.59K.
Market Cap€1.23B
Enterprise Value€6.59K
Share Statistics
Consun Pharmaceutical Group Ltd. has 841,547,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding841,547,100
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Consun Pharmaceutical Group Ltd.’s return on equity (ROE) is 0.24 and return on invested capital (ROIC) is 21.08%.
Return on Equity (ROE)0.24
Return on Assets (ROA)0.17
Return on Invested Capital (ROIC)21.08%
Return on Capital Employed (ROCE)0.24
Revenue Per Employee1.20M
Profits Per Employee420.24K
Employee Count2,847
Asset Turnover0.53
Inventory Turnover2.76
Valuation Ratios
The current PE Ratio of Consun Pharmaceutical Group Ltd. is 8.4. Consun Pharmaceutical Group Ltd.’s PEG ratio is 0.83.
PE Ratio8.4
PS Ratio3.52
PB Ratio2.65
Price to Fair Value2.65
Price to FCF10.51
Price to Operating Cash Flow7.67
PEG Ratio0.83
Income Statement
In the last 12 months, Consun Pharmaceutical Group Ltd. had revenue of 3.42B and earned 1.08B in profits. Earnings per share was 1.26.
Revenue3.42B
Gross Profit2.67B
Operating Income1.20B
Pretax Income1.20B
Net Income1.08B
EBITDA1.21B
Earnings Per Share (EPS)1.26
Cash Flow
In the last 12 months, operating cash flow was 1.28B and capital expenditures -68.19M, giving a free cash flow of 1.21B billion.
Operating Cash Flow1.28B
Free Cash Flow1.21B
Free Cash Flow per Share1.44
Dividends & Yields
Consun Pharmaceutical Group Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.35
52-Week Price Change-7.92%
50-Day Moving Average1.47
200-Day Moving Average1.60
Relative Strength Index (RSI)45.89
Average Volume (3m)815.00
Important Dates
Consun Pharmaceutical Group Ltd. upcoming earnings date is Mar 24, 2027, TBA (Not Confirmed).
Last Earnings DateAug 26, 2026
Next Earnings DateMar 24, 2027
Ex-Dividend Date―
Financial Position
Consun Pharmaceutical Group Ltd. as a current ratio of 3.22, with Debt / Equity ratio of 4.82%
Current Ratio3.22
Quick Ratio3.03
Debt to Market Cap0.02
Net Debt to EBITDA-0.88
Interest Coverage Ratio275.77
Taxes
In the past 12 months, Consun Pharmaceutical Group Ltd. has paid 107.29M in taxes.
Income Tax107.29M
Effective Tax Rate0.09
Enterprise Valuation
Consun Pharmaceutical Group Ltd. EV to EBITDA ratio is 9.07, with an EV/FCF ratio of 9.58.
EV to Sales3.20
EV to EBITDA9.07
EV to Free Cash Flow9.58
EV to Operating Cash Flow9.03
Balance Sheet
Consun Pharmaceutical Group Ltd. has €3.95B in cash and marketable securities with €213.01M in debt, giving a net cash position of €3.74B billion.
Cash & Marketable Securities€3.95B
Total Debt€213.01M
Net Cash€3.74B
Net Cash Per Share€4.44
Tangible Book Value Per Share€5.36
Margins
Gross margin is 80.09%, with operating margin of 35.18%, and net profit margin of 31.55%.
Gross Margin80.09%
Operating Margin35.18%
Pretax Margin35.01%
Net Profit Margin31.55%
EBITDA Margin35.34%
EBIT Margin33.71%
Analyst Forecast
The average price target for Consun Pharmaceutical Group Ltd. is €2.02, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€2.02
Price Target Upside19.02% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast6.93%
EPS Growth Forecast12.07%